The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

Gazyva Increases PFS in Phase III Trial Of Indolent Non-Hodgkin’s Lymphoma Patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Patients with indolent non-Hodgkin’s lymphoma lived significantly longer without disease worsening or death when treated with Gazyva (obinutuzumab) plus bendamustine and followed by Gazyva alone, compared to bendamustine alone.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Guest Editorial

When “safe and effective” is not “reasonable and necessary”
We can curb excessive drug dosing and improve the quality of cancer care

By law, the Food and Drug Administration is required to determine whether a drug, device, biologic, or medical device is “safe and effective.” But the FDA determination does not control whether the Centers for Medicare & Medicaid Services will pay for it.  To satisfy CMS, medical products and services must be “reasonable and necessary,” meaning...

By Mark J. Ratain and David A. Hyman
ClinicalTrials & Tribulations

A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease.  The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

By Kevin King

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account